Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Total Liabilities
Everything the company owes to creditors and other parties.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 27.9% from a year ago
Total liabilities stood at $1.67B at the end of Q1 FY2026, down 27.9% from a year earlier and down 24.2% from the prior quarter. Over 3 fiscal years it compounded at -7.0% a year.
Context
- Total liabilities amounted to 52.7% of total assets at the end of Q1 FY2026, down 14.4 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -27.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.21B USD
- Year-over-year change
- -9.3%
- 4-year CAGR
- -0.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.21B | -9.3% |
| FY2024 | 2024-12-31 | 2.44B | +1.3% |
| FY2023 | 2023-12-31 | 2.41B | -12.3% |
| FY2022 | 2022-12-31 | 2.74B | +23.6% |
| FY2021 | 2021-12-31 | 2.22B | — |
Total Liabilities vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's Mar 2026 total liabilities of $1.67B is the 4th highest of the 11 companies compared; the peer median is $104.83M.
- Its year-over-year change of -27.9% is the 8th highest of 11, against a peer median of +1.5%.
- Total liabilities amounts to 52.7% of total assets for SRPT, versus a peer median of 16.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $4.2B | -2.6% | +4.1% | 75.6% | |
| Jun 2026 | $3.42B | +20.2% | +14.8% | 105.1% | |
| Sep 2026 | $2.52B | +4.3% | +15.7% | 86.5% | |
| Mar 2026 | $1.67B | -27.9% | -7.0% | 52.7% | |
| Jun 2026 | $291.86M | +85.3% | +58.5% | 29.4% | |
| Mar 2026 | $137.84M | -33.2% | -15.7% | 18.2% | |
| Mar 2026 | $71.81M | -38.4% | -16.3% | 12.3% | |
| Mar 2026 | $48.76M | -1.4% | +2.6% | 11.5% | |
| Mar 2026 | $47.58M | +82.2% | +9.4% | 14.6% | |
| Mar 2026 | $22.32M | -37.3% | -11.2% | 14.3% | |
| Mar 2026 | $12.39M | +29.6% | -0.3% | 5.4% | |
| Peer median (excluding SRPT) | $104.83M | +1.5% | +3.4% | 16.4% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.12B | 966.78M | 428.43M | 1.1B | 801.28M |
| Short-term Investments | 0 | 1.02B | 1.25B | 251.78M | 138.37M |
| Net Receivables | 172.75M | 261.6M | 436.98M | 649.73M | 519.61M |
| Inventory | 186.21M | 203.97M | 322.86M | 749.96M | 914.74M |
| Other Current Assets | 5.3M | 6.82M | 12.48M | 9.21M | 9.2M |
| Total Current Assets | 2.6B | 2.56B | 2.58B | 3.07B | 2.54B |
| Property, Plant & Equipment (Net) | 236.69M | 244.99M | 357.11M | 488.65M | 470.62M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 14.24M | 7.58M | 29.62M | 26.89M | 28.95M |
| Long-term Investments | 34.89M | 31.32M | 6.53M | 136.87M | 1.05M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 258.06M | 286.62M | 291.99M | 237.3M | 311.15M |
| Total Non-current Assets | 543.88M | 570.51M | 685.25M | 889.71M | 811.77M |
| Total Assets | 3.15B | 3.13B | 3.26B | 3.96B | 3.35B |
| Account Payables | 76.74M | 95.88M | 164.92M | 214.44M | 280.84M |
| Short-term Debt | 0 | 0 | 105.48M | 0 | 0 |
| Tax Payables | 216K | 12.52M | 13.77M | 17.39M | 0 |
| Deferred Revenue | 89.24M | 89.24M | 50.42M | 130.26M | 443.4M |
| Other Current Liabilities | 110.44M | 134.73M | 178.81M | 200.28M | 176.13M |
| Total Current Liabilities | 452.73M | 619.6M | 653.66M | 731.68M | 1.1B |
| Long-term Debt | 1.1B | 1.54B | 1.13B | 1.14B | 828.97M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 574.24M | 485M | 437M | 325M | 83.91M |
| Other Non-current Liabilities | 54.6M | 36.94M | 41.1M | 49.15M | 1.53M |
| Total Non-current Liabilities | 1.77B | 2.12B | 1.75B | 1.7B | 1.11B |
| Total Liabilities | 2.22B | 2.74B | 2.41B | 2.44B | 2.21B |
| Common Stock | 9K | 9K | 9K | 10K | 11K |
| Retained Earnings | (3.21B) | (3.91B) | (4.45B) | (4.21B) | (4.88B) |
| Accumulated OCI | (20K) | (1.66M) | 918K | (218K) | 272K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 928.01M | 384.95M | 859.34M | 1.53B | 1.14B |
| Total Debt | 1.15B | 1.62B | 1.4B | 1.34B | 1.04B |
| Net Debt | (962.43M) | 650.58M | 968.38M | 240.06M | 238.46M |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.